title: Comment on "deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial".
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
authors.forename: Antoine N
authors.initials: AN
authors.lastname: Saliba
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
authors.forename: Ali T
authors.initials: AT
authors.lastname: Taher
mesh_terms: D003676:Deferoxamine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D019190:Iron Overload / Q000628:therapy*; D008297:Male; D011728:Pyridones / Q000008:administration & dosage*; D017086:beta-Thalassemia / Q000628:therapy*
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D003676:Deferoxamine